All Sections

In the last decades, cancer therapies have substantially improved cancer care and patients’ survival. The introduction of targeted therapies had a major impact on the management of cancer. However, millions of people still die from cancer every year and cancer drug resistance remains the Achil...

The MDPI journal Cancers has recently defined the scope and have introduced a Tumor Microenvironment Section. The TME section aims to publish high-quality research on the molecular and cellular components of cancer microenvironment, with a particular focus on basic, translational and clinical resear...

Aims and scope Systematic reviews and meta-analyses are considered the highest level in the “pyramid of evidence”. In clinical practice guidelines, it is recommended that multiple studies are conducted in the same setting, and, in this case, a systematic review (with meta-analysis) real...

Pediatric tumors represent a largely unique and distinct group of tumors as compared to adult cancer, with some overlap in cancer types that occur in adolescents and young adults. In relation to the young patient age, etiology and pathogenesis are frequently completely different from adults, which i...

Dysregulation of the complex biological processes that control cell and tissue homeostasis, growth and development under physiological conditions is the key driver of oncogenesis, tumor progression and therapy resistance of cancer. A better understanding of the pivotal molecular events underlying th...

The development of new methods and technologies for early diagnosis and effective treatment and monitoring of cancer is essential for the improvement of prognosis and overall survival of patients. In this section of Cancers, we welcome contributions from researchers describing new methods and techno...

Clinical Research in Cancer is a dedicated Section of the journal Cancers that publishes high-quality, peer-reviewed clinical investigations aimed at advancing the understanding, prevention, diagnosis, and management of cancer in human populations. This Section encompasses a broad scope of clinical ...

In the current era of precision medicine, cancer biomarkers provide critical data for predicting responses to therapies, generating prognoses of disease outcomes, and in determining oncogenic risk. Biomarkers are increasingly important as companions for drug discovery and development, and can help g...

The fundamental abnormality driving the onset and progression of all cancer types is the dysregulated proliferation of cells that grow and divide in an uncontrolled manner, invade normal tissues and organs, and ultimately disseminate throughout the body. This loss of growth control arises from the p...

Cancer survivors are now living longer thanks to a better understanding of this cancer’s biology and the development of new treatment regimens. However, they continue to face long-term consequences of the disease and its treatment. Understanding the mechanism of survivorship can help to improv...

Tumor metastasis is one of the hallmarks of cancer and is considered to be the main cause of death for most cancer patients. The process of metastasis is very complex as the characteristics of invading tumor cells are driven by various epigenetic and genetic changes. It is well known that the primar...

The availability of large cancer- and health-related data sets offers promise for understanding the genetic basis as well as the mechanisms of the initiation and progression of cancer. However, to optimally use and exploit large databases, optimal informatics and data analytics methods and tools, as...

Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for adva...

Despite the great advances made in cancer therapy, prevention remains the cornerstone for diminishing cancer mortality. Accordingly, increasing epidemiology knowledge is crucial for identifying adequate preventive measures. Many efforts have been made to understand what is causing a specific cancer ...

Cancer represents a major public health challenge and is the second leading cause of death in the United States. The World Health Organization estimates that, by the year 2035, there will be 24 million new cancer cases and 14.4 million cancer-related deaths each year. Thanks to the remarkable progre...

The future of cancerology, considering environmental pollution and technological advancements in cancer screening and diagnosis, is dependent on our efforts today toward better identifying the causes of cancer, improving screening and, also, the establishment and use of new diagnostic tests. The se...